Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ALK-abello A/S Class B (AKBLF)
OTHER OTC:AKBLF
Holding AKBLF?
Track your performance easily
AKBLF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$14.90 - $28.00
Previous CloseN/A
Volume1.00
Average Volume (3M)3.00
Market Cap
$4.60B
Enterprise Value$37.99B
Total Cash (Recent Filing)$840.00M
Total Debt (Recent Filing)$758.00M
Price to Earnings (P/E)40.3
Beta1.03
Next Earnings
Feb 19, 2025EPS Estimate
0.17Last Dividend Ex-Date
Mar 16, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)0.52
Shares Outstanding202,567,200
10 Day Avg. Volume0
30 Day Avg. Volume3
Standard Deviation0.23
R-Squared0.17
Alpha-0.00038
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.09
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap8.25
Enterprise Value/Revenue8.42
Enterprise Value/Gross Profit13.61
Enterprise Value/Ebitda53.58
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
ALK-abello News
PremiumCompany Announcements
ALK-Abelló A/S Reports Strong Q3 Growth
Options Prices
Currently, No data available
---
Ownership Overview
0.04% Insiders
3.75% Mutual Funds
― Other Institutional Investors
91.45% Public Companies and
Individual Investors
AKBLF FAQ
What was ALK-abello A/S Class B’s price range in the past 12 months?
ALK-abello A/S Class B lowest stock price was $14.90 and its highest was $28.00 in the past 12 months.
What is ALK-abello A/S Class B’s market cap?
ALK-abello A/S Class B’s market cap is $4.60B.
When is ALK-abello A/S Class B’s upcoming earnings report date?
ALK-abello A/S Class B’s upcoming earnings report date is Feb 19, 2025 which is in 28 days.
How were ALK-abello A/S Class B’s earnings last quarter?
ALK-abello A/S Class B released its earnings results on Nov 14, 2024. The company reported $0.138 earnings per share for the quarter, beating the consensus estimate of $0.109 by $0.029.
Is ALK-abello A/S Class B overvalued?
According to Wall Street analysts ALK-abello A/S Class B’s price is currently Overvalued.
Does ALK-abello A/S Class B pay dividends?
ALK-abello A/S Class B pays a Notavailable dividend of $0.035 which represents an annual dividend yield of N/A. See more information on ALK-abello A/S Class B dividends here
What is ALK-abello A/S Class B’s EPS estimate?
ALK-abello A/S Class B’s EPS estimate is 0.17.
How many shares outstanding does ALK-abello A/S Class B have?
ALK-abello A/S Class B has 202,567,200 shares outstanding.
What happened to ALK-abello A/S Class B’s price movement after its last earnings report?
ALK-abello A/S Class B reported an EPS of $0.138 in its last earnings report, beating expectations of $0.109. Following the earnings report the stock price went down -1.224%.
Which hedge fund is a major shareholder of ALK-abello A/S Class B?
Currently, no hedge funds are holding shares in AKBLF
---
Company Description
ALK-abello A/S Class B
ALK-Abello A/S engages in the production and development of pharmaceutical products to prevent and treat allergies. It also manufactures tablet-based allergy vaccines for pollen, house dust mites, animals, and insect stings. Its treatment comprises allergy vaccines, emergency treatment, and allergy diagnostics. The company was founded by Poul Christian Krejner Tejn Barfod on June 9, 1923 and is headquartered in Horsholm, Denmark.
---
AKBLF Company Deck
---
AKBLF Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a robust performance in several areas, including strong organic revenue growth and significant improvements in EBIT margin. Recovery in Jext sales and a major licensing deal with ARS Pharma highlight strategic advancements. However, challenges remain in North America with sluggish growth, underperformance of PRE-PEN, and delays in the Chinese market. Overall, the positives slightly outweigh the negatives, indicating a generally optimistic outlook.Read More>---
Technical Analysis
Dynavax
―
Inovio Pharmaceuticals
―
Aclaris Therapeutics
―
Emergent Biosolutions
―
Novartis
―
Bristol-Myers Squibb
―
---